<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02943655</url>
  </required_header>
  <id_info>
    <org_study_id>HVB</org_study_id>
    <nct_id>NCT02943655</nct_id>
  </id_info>
  <brief_title>Treatment of Heavy and/or Prolonged Menstrual Bleeding Without Organic Cause</brief_title>
  <official_title>Combined Oral Contraceptives, Progestogens, and Non-steroidal Anti-inflammatory Drugs for Heavy and/or Prolonged Menstrual Bleeding Without Organic Cause</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Abnormal uterine bleeding encompasses abnormalities in the regularity, duration of flow,&#xD;
      frequency, and/or blood flow volume relative to normal menstruation. Of these menstrual&#xD;
      abnormalities, heavy menstrual bleeding (HMB), defined objectively as a blood loss of 80 ml&#xD;
      or more per menstrual cycle , which is unrelated to pregnancy or known pelvic or systemic&#xD;
      disease.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 1, 2017</start_date>
  <completion_date type="Actual">February 10, 2021</completion_date>
  <primary_completion_date type="Actual">October 10, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the amount of menstrual blood loss</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">240</enrollment>
  <condition>Improve Quality of Life</condition>
  <condition>Heavy Menstrual Bleeding</condition>
  <arm_group>
    <arm_group_label>combined oral contraceptives</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>oral second generation pills one tablet daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>medroxyprogesterone acetate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>oral 5 mg daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>non-steroidal anti-inflammatory</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>oral 500 mg mefenamic acid three times per day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>combined contraceptive pills (microcept)</intervention_name>
    <description>oral combined contraceptive once daily</description>
    <arm_group_label>combined oral contraceptives</arm_group_label>
    <other_name>microcept</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>medroxyprogesterone acetate (progest)</intervention_name>
    <description>oral 5 mg medroxyprogesterone acetate daily</description>
    <arm_group_label>medroxyprogesterone acetate</arm_group_label>
    <other_name>progest</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mefenamic acid (ponstan forte)</intervention_name>
    <description>oral 500 mg mefenamic acid three times per day</description>
    <arm_group_label>non-steroidal anti-inflammatory</arm_group_label>
    <other_name>ponstan forte</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Regular menstrual cycles with BMI (19-29 kg/m2). Heavy and/or prolonged menstrual bleeding&#xD;
        involving at least last three consecutive menstrual cycles.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Postmenopausal bleeding (over one year since the last menstrual period).&#xD;
&#xD;
          2. Irregular menses or intermenstrual bleeding.&#xD;
&#xD;
          3. Organic causes of heavy menstrual bleeding suspected or confirmed by experienced&#xD;
             abdominal and transvaginal ultrasound after thorough general and gynecological&#xD;
             examination.&#xD;
&#xD;
          4. Iatrogenic (treatment-related) causes of heavy menstrual bleeding (e.g.&#xD;
             non-progestogen-releasing intrauterine contraceptive device, oral contraceptives,&#xD;
             other hormonal drug use or anticoagulant agent).&#xD;
&#xD;
          5. Iron deficiency anemia.&#xD;
&#xD;
          6. History of chronic diseases known to interfere with menstrual bleeding or prevent the&#xD;
             use of any of the listed drugs e.g previous or current thromboembolic disease.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Ahmed Abbas</name>
      <address>
        <city>Assiut</city>
        <state>Cairo</state>
        <zip>002</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>October 21, 2016</study_first_submitted>
  <study_first_submitted_qc>October 24, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 25, 2016</study_first_posted>
  <last_update_submitted>June 1, 2021</last_update_submitted>
  <last_update_submitted_qc>June 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Ahmed Mohamed Abbas</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Menorrhagia</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mefenamic Acid</mesh_term>
    <mesh_term>Medroxyprogesterone Acetate</mesh_term>
    <mesh_term>Contraceptive Agents</mesh_term>
    <mesh_term>Medroxyprogesterone</mesh_term>
    <mesh_term>Progesterone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

